Evolus (EOLS) Total Non-Current Liabilities (2017 - 2021)
Evolus (EOLS) reported Total Non-Current Liabilities of $130.9 million for Q4 2021, down 45.58% on a YoY basis from $240.5 million in Q4 2020, and down 45.58% quarter-over-quarter from $240.5 million in Q4 2020.
Evolus (EOLS) Total Non-Current Liabilities (2017 - 2021) Analysis & Trends
Evolus has reported Total Non-Current Liabilities for 5 years, with the latest figure at $130.9 million in Q4 2021.
- For the quarter ending Q4 2021, Total Non-Current Liabilities fell 45.58% year-over-year to $130.9 million; the trailing twelve-month figure through Dec 2021 stood at $130.9 million (down 45.58% YoY), and the FY2021 full-year result was $130.9 million, down 45.58% from the prior year.
- Total Non-Current Liabilities for Q4 2021 stood at $130.9 million, down from $240.5 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $240.5 million in Q4 2020, with the low at $34.8 million in Q1 2018.
- Historically, Total Non-Current Liabilities has averaged $108.3 million across 5 years, with a median of $114.4 million in 2019.
- Annual changes were most pronounced in 2018 — Total Non-Current Liabilities slumped 83.64% — and 2019, when it jumped 225.1%.
- Evolus' Total Non-Current Liabilities stood at $227.8 million in 2017, then tumbled by 83.64% to $37.3 million in 2018, then surged by 212.14% to $116.3 million in 2019, then soared by 106.77% to $240.5 million in 2020, then sank by 45.58% to $130.9 million in 2021.
- The last three Total Non-Current Liabilities figures came in at $130.9 million (Q4 2021), $240.5 million (Q4 2020), and $117.3 million (Q1 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.13 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.81 Bn |
| 10 | Evolus | 435.45 Mn | 385.65 Mn | 48.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 130.87 Mn |
| Dec 31, 2020 | 240.48 Mn |
| Mar 31, 2020 | 117.33 Mn |
| Dec 31, 2019 | 116.30 Mn |
| Jun 30, 2019 | 114.43 Mn |
| Mar 31, 2019 | 99.67 Mn |
| Dec 31, 2018 | 37.26 Mn |
| Sep 30, 2018 | 37.31 Mn |
| Jun 30, 2018 | 35.20 Mn |
| Mar 31, 2018 | 34.81 Mn |
| Dec 31, 2017 | 227.78 Mn |